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The impact of renal insufficiency on the dispositions of 300 mg of orally administered ceftibuten-cis, a new
broad-spectrum oral cephalosporin, and its primary metabolite ceftibuten-trans was characterized in 30 adult
subjects. Subjects were divided into five groups of six subjects each on the basis of their 24-h ambulatory
creatinine clearances (CLCR). The apparent total body clearance (CLp/F; where F is absolute bioavailability)
and renal clearance of ceftibuten-cis were significantly lower in subjects with end-stage renal disease (on
maintenance hemodialysis; group V) and in those with severe (CLCR, 5 to 29 ml/min; group IV) and moderate
(CLCR, 30 to 49 ml/min; group Ill) renal insufficiency than in those with mild ren)al insufliciency (CLCR, 50 to
80 ml/min; group II) or normal renal function (CLCR, >80 ml/min; group I). A significant correlation was
observed between CLcR and ceftibuten-cis CLp/F. The mean apparent steady-state volume of distribution
(Vp/F) of ceftibuten-cis ranged from 0.21 to 0.24 liter/kg in subjects in group I, I, m, and IV. V/F was
significantly greater in the group V subjects with end-stage renal disease (V/F, 0.39 + 0.27 liters/kg). These
changes in Vp/F cannot be separated from possible changes in bioavailability. The maximum concentration of
ceftibuten-trans in plasma was significantly higher and occurred significantly later in group IV subjects than it
did in subjects in the other groups. The terminal elimination half-life of ceftibuten-trans was significantly and
progressively prolonged as CLCR declined (2.63 ± 1.02, 5.37 ± 1.93, 14.29 ± 10.84, and 19.46 ± 9.69 h in
groups I, II, III, and IV, respectively). The hemodialysis clearance of ceftibuten-cis was 76.9 ± 18.0 ml/min,
and the fraction of the administered dose of ceftibuten-cis removed during -3 h of hemodialysis-was 39 ±%.
Ceftibuten dosage adjustments are proposed for subjects with renal insufficiency.
Ceftibuten {(6R,7R)-7[(2)-2-(2-aminothiazol-4-yl)-4 carboxy-
2-butenyolamino]-8-oxo-5-thia-1-azabicyclo [4,2,0] oct-2-
ene-2 carboxylic acid; molecular weight, 410.43} (Fig. 1) is
an investigational, orally active broad-spectrum cephalospo-
rin that has demonstrated in vitro antibacterial activity
against a wide range of gram-negative and gram-positive
bacteria (6). In vitro studies have shown that 92% of all
members of the family Enterobacteriaceae are susceptible to
ceftibuten, whereas 78.7 and 45.1% are susceptible to ce-
fixime and cefuroxime, respectively (7). The activity of
ceftibuten against 95 respiratory tract pathogens was supe-
rior or comparable to that reported for other oral cephalo-
sporins such as cefprozil (BMY-28100), cefuroxime axetil,
cefetamet (RO 15-8074), cefteram (RO 19-5247), and ce-
fixime (7).
Ceftibuten is administered as the active cis isomer and is
excreted primarily in the urine. Approximately 70% of
ceftibuten-cis is excreted unchanged in the urine of healthy
volunteers, and the terminal elimination half-life (t12|2) is 2 to
3 h (1). Plasma protein binding of ceftibuten-cis approxi-
mates 65% in healthy subjects and is independent of the
ceftibuten-cis concentration in plasma (12). During multiple
dosing of 200 mg of ceftibuten-cis twice daily in normal male
volunteers, 94% of the drug was excreted in the urine (and
* Corresponding author.
t Present address: University of Pittsburgh, Pittsburgh, PA
15260.
thus absorbed) as unchanged ceftibuten and the trans isomer
(1). Following oral administration, the metabolite ceftibuten-
trans (antimicrobial activity, approximately one eighth that
of the cis isomer) is qetected in the plasma and accounts for
7 to 10% of the dose recovered in the urine of healthy
subjects with normal renal function (1). In vitro experiments
have documented seroconversion of the cis and trans iso-
mers of ceftibuten (12).
This study was designed to characterize the disposition of
ceftibuten-cis following the administration of a single oral
dose to subjects with various degrees of renal function and to
assess the effect of hemodialysis on the disposition of
ceftibuten.
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FIG. 1. Structure of ceftibuten.
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TABLE 1. Subject demographic dataa
Subject SeM/ Age Wt Ht CLCR Ceftibuten-cis
groupa (no. M/ (yr) (kg) (cm) (ml/min) dose (mg/kg)
no. F)b yr
Group I
Mean 5/1 37.7 84.4 176.5 117.3 3.6
SD 15.7 11.2 9.7 26.3 0.6
Range 27-57 90.5-161.6
Group II
Mean 5/1 56.3c 79.7 169.1 75.6 3.9
SD 10.5 14.4 13.3 3.7 0.7
Range 40-68 70.6-79.8
Group III
Mean 5/1 53.5 78.5 175.0 36.2 4.0
SD 16.2 17.3 5.2 2.7 1.0
Range 30-70 31.2-38.7
Group IV
Mean 3/3 52.5 73.9 171.0 16.1 4.2
SD 13.8 16.7 12.8 7.2 0.9
Range 28-63 7.1-27.3
Group V
Mean 3/3 52.2 58.9d 166.2 2.9e 5.3f
SD 11.5 12.3 11.3 4.1 1.0
Range 39-68 2.5-10.3
a There were six subjects in each group.
b M, male; F, female.
c Versus group I, P < 0.05.
d Versus groups I, II, and III, P < 0.05.
eThree subjects were anuric; therefore, n = 3 for CLCR-
f Versus groups I, II, III, and IV, P < 0.05.
MATERIALS AND METHODS
Subjects and study design. Thirty subjects between the
ages of 25 and 74 years participated in this study. The
subjects were divided into five groups on the basis of their
24-h ambulatory creatinine clearance (CLCR). Subjects in
group I had normal renal function (CLCR, >80 ml/min).
Those in groups II, III, and IV were nondialyzed subjects
with mild (CLCR, 50 to 80 mlmin), moderate (CLCR, 30 to 49
ml/min), or severe (CLCR, 5 to 29 ml/min) renal insufficiency,
respectively. Subjects in group V were maintained on
chronic hemodialysis three times weekly for a minimum of
12 weeks prior to entry into the study.
The study was approved by the Hennepin County Medical
Center's institutional review board. All subjects granted
written informed consent before initiation of the study and
underwent a complete physical examination, including elec-
trocardiogram, a 24-h ambulatory CLCR, urinalysis, com-
plete blood count with differential, and a multichannel
chemistry profile before and after study completion.
None of the subjects had a history of or current evidence
of hepatic disease, cardiovascular disorders, respiratory
disease, gastrointestinal disorders, blood dyscrasias, rapidly
changing renal function as addressed by historical data, or
cancer. None of the subjects had received a renal transplant,
nor had they received an investigational drug during the 4
weeks prior to thie study. Concurrent drug therapy included
standard therapy for diseases related to renal insufficiency,
such as hypertension, diabetes, and hyperparathyroidism.
Subjects were not on concomitant drug therapy known to
affect the metabolic capacity or renal handling of drugs.
These medications were continued unchanged for at least 14
days prior to the study and during the course of the investi-
gation.
Subjects reported to the Clinical Research Unit of the
Drug Evaluation Unit the evening prior to drug administra-
tion. During the 10 h prior to dosing they fasted, with the
exception of water and concomitant medications such as
antihypertensive and oral antidiabetic agents. Drugs that
could alter absorption characteristics (i.e., antacids and
phosphate binders), gastrointestinal motility (i.e., metoclo-
pramide and bisacodyl), or that were not essential (i.e.,
vitamin replacements) were not administered until 4 h after
II
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FIG. 2. Ceftibuten-cis plasma concentration-versus-time profiles (mean ± SD) for group I (0), group 11 (0), group III (A), group IV (A),
and group V (interdialytic dose; O) subjects following a 300-mg oral dose of ceftibuten.
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TABLE 2. Ceftibuten-cis pharmacokinetic parameters
Subject Cmax Cmax Tmax AUCO ,B tl/21V3F CLp/F % of total doseSubjectCrnaxC"' x 13/F ~~~~~~~~~~~recovered in CLR CLNR/Fgroup (mg/liter) (mg/liter/kg) (h) (mg hMiter) (h1) (h) (liter/kg) (ml/min) urine as i (ml/min) (m/min)
Group I
Mean 11.7 0.14 2.67 65.6 0.26a,b,c,d 2.70 0.21 76.7a,b,c,d 67.7a,b,c,d 51.7abcd 250c,d
SD 2.3 0.04 0.52 5.5 0.05 0.58 0.03 6.8 9.5 6.4 8.7
Group II
Mean 13.9 0.18 2.83 94.1 019b,c,d 3.85 0.22 547b,c,d 52.6cd 28.6b,c,d 26.b,c,d
SD 2.0 0.04 0.75 18.5 0.06 1.26 0.05 9.8 9.5 6.6 8.2
Group III
Mean 13.0 0.16 3.17 167.7e 0.10d 7.07 0.24 30.2c,d 41.1d 12.2c,d 18.0
SD 6.5 0.08 0.75 18.3 0.02 1.43 0.07 3.2 11.2 2.8 5.0
Group IV
Mean 20.7b,e 0.31a,b,e 4.33a,b,d,e 362 9a,b,e 0.07 13.39a,b,e 0.22 16.2 31.0d 5.6 10.6
SD 7.4 0.16 1.37 144.6 0.05 4.67 0.05 7.7 14.6 5.3 3.6
Group Vf
Mean 19.5e 034a,b,e 3.0 472.2a,b,c,e 0.03 22.28a,b,ce 0.39a,C,e 11.3 18.0k 2.19 9.2
SD 6.4 0.14 0.89 102.9 0.01 7.92 0.27 2.7 7.2 1.4 1.7
a Versus group II, P < 0.05.
b Versus group III, P < 0.05.
c Versus group IV, P < 0.05.
dVersus group V, P < 0.05.
eVersus group I, P < 0.05.
f Interdialytic period.
g Three subjects were anuric; therefore, n = 3 for these parameters.
ceftibuten administration. Each subject was given three
100-mg capsules of ceftibuten-cis (lot FMR 87677DOZ;
Schering-Plough Corporation, Kenilworth, N.J.) with 120 ml
of water at approximately 8 a.m. The subjects remained
ambulatory for 2 h after drug administration and remained
fasting for 4 h after the dose, when a standardized lunch was
served.
140
120
100
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Subjects in groups I to IV were confined to the research
facility for 48 h after drug administration, to facilitate the
collection of blood and urine samples. These subjects also
returned to the research facility at 72, 96, and 120 h after
drug administration to return urine collections. The final
blood sample was obtained at the 72-h visit. Subjects in
group V received the drug on two separate occasions, an
0
0
0 20 40 60 80 100 120 140 160 180
creatbi wC bo (m1/Mt)
FIG. 3. Relationship of the ceftibuten-cis CLp/F versus CLCR (in millimeters per minute); CLp/F = (0.569 * CLCR) + 0.957 (n = 24; for
groups I to IV, r2 = 0.855, P < 0.05).
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interdialytic day and a hemodialysis day. On the interdialytic
day, they followed the same procedures as those subjects in
study groups I to IV. At least 2 weeks after receiving their
first dose, subjects in group V returned to the unit the
evening before they were to receive the second dose. They
fasted for 10 h, with the exception of water and their
required concomitant medications. At 4 h before their regu-
larly scheduled hemodialysis procedure, each patient re-
ceived three 100-mg capsules of ceftibuten-cis orally with
120 ml of water. A high-efficiency dialyzer was used for all
of the hemodialysis procedure. Five of the six subjects
were dialyzed with a Travenol CA-210 hollow-fiber dialysis
filter (Travenol Laboratories, Deerfield, Ill.). The membrane
is made of cellulose acetate with 15-,um wall thickness
and 2.1-iM2 surface area. One patient was dialyzed with a
Travenol CA-170 filter, which has a membrane surface area
of 1.7 M2. All other characteristics of the Travenol CA-
170 and Travenol CA-210 filters were comparable. The
electrolyte and glucose concentrations of the dialysate con-
tent were standardized, with the exception of potassium
content, which varied according to the patient's clinical
status.
Sample collection. Blood samples (7 ml) were obtained
from subjects in groups I to IV and group V (interdialytic
dose) immediately prior to drug administration and at 1, 2, 3,
4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 h after dosing.
All blood samples were drawn into heparinized Vacutainer
tubes. Plasma was harvested within 15 min of each sample
collection. The plasma was pipetted into appropriately la-
beled polypropylene tubes, frozen, and maintained at -70°C
until analysis.
The total urine outputs of subjects in groups I to IV were
collected during the following time intervals: before (-12 to
0 h) and 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to
48, 48 to 72, 72 to 96, and 96 to 120 h after drug administra-
tion. Urine volumes were quantified, and an aliquot was
saved at -70°C until analysis.
During the hemodialysis phase for group V subjects, blood
samples were obtained immediately before and at 0.5, 1, 2,
and 3 h after drug administration. Paired arterial (predialysis
filter) and venous (postdialysis filter) blood samples were
obtained prior to and 0.5, 1, 2, and 3 h after the start of
hemodialysis. Additional blood samples were obtained im-
mediately at the cessation of hemodialysis and at 0.16, 0.33,
0.5, 0.75, 1, 2, 12, 24, 36, and 48 h after the end of
hemodialysis.
For those subjects in group V who were not anuric, urine
was collected during the following time intervals after each
drug administration: 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12
to 24, and 24 to 48 h. Urine volumes were quantified, and an
aliquot sample was saved at -70°C until analysis.
During the hemodialysis procedure, quantitated dialysate
collections were performed over the following intervals after
the initiation of hemodialysis: 0 to 0.5, 0.5 to 1, 1 to 2, and 2
to 3 h and 3 h to the end of hemodialysis. The total volume
was measured, and an aliquot was frozen at -70°C until
analysis.
Analytic procedures. The plasma, urine, and dialysate
samples were analyzed for ceftibuten-cis and ceftibuten-
trans by a high-performance liquid chromatography method
at Schering-Plough Corporation (1). The high-performance
liquid chromatography method involves the addition of an
internal standard (acyclovir) and 100 .1l of 0.2 M sodium
phosphate buffer (pH 7) to a 100-,ul sample. A 5-p, sample of
the resulting solution was then injected into a high-perfor-
mance liquid chromatograph consisting of a ,uBondapak C18
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FIG. 4. Ceftibuten-cis concentrations (mean ± SD) in plasma following the interdialytic (0) and intradialytic (0) doses of ceftibuten-cis
for group V subjects. (Inset) Ceftibuten-cis predialysis filter (0) and postdialysis filter (V) concentration in plasma during the 3- to 12-hour
time frame after the 300-mg intradialytic oral dose of ceftibuten-cis. Hemodialysis was from 4 to 7 h (O).
column and a Waters model 440 absorbance detector with a
fixed wavelength of 254 mm. The mobile phase consisted of
acetonitrile and 0.05 M ammonium acetate (2:98; vol/vol)
delivered at a flow rate of 1 ml/min. The assay was linear
over a concentration range of 0.1 to 50 pug/ml. The high-
performance liquid chromatography technique was precise
and accurate down to 0.1 ,ug of ceftibuten-cis and ceftibuten-
trans per ml in plasma and dialysate and 0.5 ,ug/ml in urine.
The intra- and interassay coefficients of variation were less
than 5% in plasma, urine, and dialysate at concentrations of
5, 10, and 20 ,g/ml (12).
Data analysis. The maximum ceftibuten-cis and ceftibuten-
trans concentrations in plasma (Cmaxs) and time to Cm..ax(Tm,n) were determined by visual inspection of the plasma
concentration-time curves. The terminal elimination rate
constant (p) was estimated by nonlinear regression analysis
(PCNONLIN, version 3.0; Statistical Consultants, Inc.,
Lexington, Ky.) (10) of the terminal segment of the postab-
sorptive or postformation plasma concentration-time curve.
In all cases, regressions were carried out from the 8-h
postdose sample through the last measured concentration in
plasma. t1/2,3 was calculated as t1/2,3 = 0.693/p. The area
under the plasma concentration-time curve from zero to the
last time point (AUC-,) was calculated by the linear trape-
zoidal method. The residual AUC beyond the last datum
point (AUC,) was calculated as the product of the last
ceftibuten concentration in plasma and 1/a. The apparent
total body clearance (CLpJF) of ceftibuten-cis was deter-
mined as CLp/F = dose/AUC,, where F is the absolute
bioavailability of the oral capsule. The apparent volume of
distribution (Vj/F) of ceftibuten-cis was calculated as VI/F
= (CLp./F)I. The renal clearance (CLR) of ceftibuten-cis
and ceftibuten-trans was calculated as CLR = Ael-t2/AUCft-t2,
where A.el-t2 is the amount of ceftibuten-cis or ceftibuten-
trans recovered in the urine within a specific time interval
(t1-t2), and AUCtl-t2 is the AUC during the same interval.
The apparent nonrenal clearance of ceftibuten-cis (CLNR/F)
was calculated as the difference between CLpIF and CLR.
The hemodialysis clearance (CLHD) of ceftibuten-cis, the
clearance of blood urea nitrogen (BUN), and CLCR were
calculated by the equation CLHD = AR/AUCHD, where AR
is the total amount of ceftibuten-cis recovered in the dialy-
sate, and AUCHD is the area under the arterial (predialysis
filter) plasma concentration-time curve during hemodialysis.
The apparent elimination rate constant of ceftibuten-cis
during hemodialysis (kHD) was estimated by nonlinear re-
gression analysis of all arterial (predialysis filter) plasma
concentrations obtained during hemodialysis.
In vivo interconversion of ceftibuten-cis and ceftibuten-
trans was not accounted for in the data analysis.
Statistical analysis. Differences in pharmacokinetic param-
eters between the five groups were evaluated by one-way
analysis of variance and the Duncan procedure post hoc test
for significance (SPSS/PC + V2.0; SPSS, Inc.). The relation-
ships between CLCR and CLp/F, CLCR and CLR, CLCR and
I, CLCR and CLNR/F, and CLCR and V3/F were assessed by
orthogonal regression analysis (9, 11). The relationship be-
tween CLCR and CLp/F was used to project the dosage
modifications of ceftibuten-cis for subjects with renal insuf-
ficiency.
Statistical significance was assessed at the P < 0.05 level.
Data are expressed as mean ± standard deviation (SD).
VOL. 35, 1991 2271
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FIG. 5. Ceftibuten-trans plasma concentration-versus-time pro-
files (mean SD) for group I (0), group II (0), group III (A), and
group IV (L) subjects following a 300-mg oral dose of ceftibuten-cis.
RESULTS
The five groups were not significantly different in sex
distribution or height (Table 1). However, subjects in group
V weighed significantly less than subjects in groups I, II, and
III. Thus, the dose of ceftibuten, in milligrams per kilogram
ofbody weight, was larger in group V subjects (P < 0.05). In
addition, subjects in group II were significantly older than
subjects in group I. The single-dose ceftibuten-cis adminis-
tration was well tolerated in all subjects.
The mean ceftibuten-cis plasma concentration-time curves
are presented in Fig. 2. The Cmax of ceftibuten-cis was
significantly higher in group IV subjects than it was group I
and III subjects (Table 2). In addition, Cmax in group V
subjects was higher than that in group I subjects. When Cmax
was adjusted for body weight, group IV and V subjects had
significantly larger Cmax values compared with those in
group I, II, and III subjects. The mean Tmax of ceftibuten-cis
was significantly longer in group IV subjects compared with
that in subjects in all other groups (Table 2).
A significant decline in the CLp/F of ceftibuten-cis was
observed as renal function declined. The mean CLp/F values
were 76.7 + 6.8, 54.7 + 9.8, 30.2 + 3.2, 16.2 + 7.7, and 11.3
+ 2.7 ml/min for subjects in groups I, II, III, IV, and V,
respectively. The CLR of ceftibuten-cis also progressively
declined as renal function declined (Table 2). Furthermore,
the CLNR/F of ceftibuten-cis significantly declined as a
function of renal insufficiency. The VpIF of ceftibuten-cis
was not significantly different between subjects in groups I,
II, III, and IV. However, Va3/F was significantly greater in
group V subjects than it was in group I, II, and IV subjects;
0.39 ± 0.27 versus 0.21 ± 0.03, 0.22 ± 0.05, and 0.22 ± 0.5
liter/kg, respectively. The tl/2,3 of ceftibuten-cis was signifi-
cantly prolonged in group V subjects compared with that in
group I, II, III, and IV subjects. Additionally, the t1/2, of
ceftibuten-cis for subjects in group IV was significantly
prolonged compared with that in subjects in groups I, II, and
III.
The ceftibuten-cis CLp/F [CLp/F = (0.569- CLCR) + 9.57;
r2 = 0.855] (Fig. 3), the ceftibuten-cis CLR [CLR =
(0.410. CLCR) - 1.82; r2 = 0.922, forced through zero], the
ceftibuten-cis p [p = (0.0019 - CLCR) + 0.042; r2 = 0.743],
and the ceftibuten-cis CLNR/F [CLNR/F = (0.133 - CLCR) +
11.3; r2 = 0.409] were all significantly correlated with CLCR.
However, changes in the V,3/F of ceftibuten-cis did not
correlate with the decline in CLCR (r2 = 0.059).
Characteristics of the hemodialysis procedures and cefti-
buten-cis pharmacokinetic parameters during and after he-
modialysis are outlined in Table 3. The time for a dialysis
procedure was 179.3 ± 37.4 min. The dialyzer clearance of
ceftibuten-cis was 76.9 + 18.0 ml/min, and the percentage of
the administered dose of ceftibuten-cis recovered in the
dialysate during hemodialysis was 39 + 9%. The CLHD of
ceftibuten-cis was 25.6% of the CLHD of BUN and 34.8% of
the CLHD of creatinine. The average elimination rate con-
stant of ceftibuten-cis for all subjects during hemodialysis
was 0.378 + 0.114 h-1, and the corresponding tl/2,3 of
ceftibuten-cis during hemodialysis was 1.97 + 0.56 h.
A rise in the ceftibuten-cis concentration in plasma was
observed in all hemodialysis subjects within 10 min after the
cessation of hemodialysis. The maximum increase in the
concentration of ceftibuten-cis in plasma occurred at 0.58 +
0.31 h after the cessation of hemodialysis and represented an
increase of 45.9 + 41.5% above the concentration in plasma
measured at the cessation of hemodialysis. Thereafter, the
ceftibuten-cis concentrations in plasma declined monoexpo-
nentially (Fig. 4). The tl,2g of ceftibuten-cis after the redis-
tribution period was 22.5 + 13.1 h and was not significantly
different from the tl/2, observed after the interdialytic dose
of ceftibuten-cis.
Interfering substances were detected in the plasma, urine,
and dialysate with the ceftibuten-trans analytical procedure
in two subjects in group IV and all subjects in group V. This
interference was not present in any biologic specimens from
the other subjects for which data are reported.
The Cmax values of ceftibuten-trans in plasma ranged from
1.18 to 2.68 mg/liter at 1.75 to 11.33 h following ceftibuten-
cis administration (Fig. 5 and Table 4). The Cmax of cefti-
buten-trans was significantly higher when it was normalized
for body weight in group IV subjects in comparison with that
in group II and III subjects, and the Tmax was significantly
prolonged in group IV subjects in comparison with that in
group I, II, and III subjects. The AUCo. of ceftibuten-trans
significantly increased as CLCR declined. The t1/2, of cefti-buten-trans was significantly shorter in group I and II
subjects than it was in group III and IV subjects. The t4/2, of
ceftibuten-trans was not significantly different than the tl/2,
of ceftibuten-cis in any of the groups. Although the CLR of
ceftibuten-trans was approximately 10 times lower in group
IV subjects compared with that in group I subjects, the
difference did not achieve statistical significance. One sub-
ject from group I and one subject from group II had
extremely high CLR values of ceftibuten-trans (group I
subject, CLR = 170 ml/min; group II subject, CLR = 141
ml/min). If these data are excluded from the analysis, the
CLR of ceftibuten-trans remains not significantly changed as
CLCR declines (25.8 ± 13.9, 23.5 + 12.0, 15.1 + 7.6, and
6.5 + 7.2 ml/min in group I, II, III, and IV subjects,
respectively).
CLCR correlated significantly with ceftibuten-trans ,B [ =
(0.0021 CLCR) + 0.011; r2 = 0.755]. The ratio of the
AUC,OO of ceftibuten-trans to ceftibuten-cis averaged 0.22,
0.20, 0.31, and 0.33 for subjects in groups I, II, III, and IV,
respectively, and were not significantly different.
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TABLE 4. Ceftibuten-trans pharmacokinetic parameters
Subject Cmax Cmax Tmax AUCo_. tl/21 CLR %ref total dose Ratio of
group (mg/liter) (mg/liter/kg) (h) (mg h/liter) (ht) (h) (ml/min) urine as trans AUCo,
Group I
Mean 2.12a 0.027 3.50 14.12 0.295a,b,c 2.63bc 49.89 9.8 0.22
SD 1.38 0.021 1.75 4.88 0.102 1.02 60.31 6.5 0.08
Group II
Mean 1.18 0.015 4.33 19.62 0.143c 5.37b,c 43.03 15.3 0.20
SD 0.11 0.003 1.39 6.76 0.051 1.93 49.05 14.5 0.03
Group III
Mean 1.71 0.022 6.67 52.20a,d 0.072 14.29 15.06 14.7 0.31
SD 0.37 0.005 2.40 16.49 0.045 10.84 7.57 7.3 0.10
Group IV
Mean 2.68ab 0.037a,b 11.33 b 111.68a,b.d 0.045 19.46 6.51e 8.7e 0.23
SD 0.32 0.008 4.64 44.90 0.024 9.69 7.23 3.9 0.14
a Versus group II, P < 0.05.
b Versus group III, P < 0.05.
c Versus group IV, P < 0.05.
d Versus group I, P < 0.05.
e There were only four subjects because of assay interference in the other two subjects.
DISCUSSION
The pharmacokinetics of ceftibuten in subjects with renal
insufficiency are markedly altered from those observed in
subjects with normal renal function. This was expected since
approximately 70% of ceftibuten-cis is recovered unchanged
in urine in subjects with normal renal function. Ceftibuten-
cis CLp/F and CLNR/F strongly correlated with CLCR. The
fact that the age of the subjects ranged from 27 to 70 years
should not influence the data from this study, since age alone
has no effect on ceftibuten disposition (1).
The significant increase in the Cmax of ceftibuten-cis in the
subjects with severe renal insufficiency may be due to a
combination of increased F and/or decreased ,B of the drug.
Renal insufficiency has been shown to reduce the F of some
drugs, while it increases the F of others (2, 5). When the
ceftibuten-cis Cmax was adjusted for body weight (i.e.,
milligrams per liter per kilogram), the resulting mean Cmax
was larger in group IV subjects than it was in group I
subjects. There was also a delay in the absorption of
ceftibuten-cis in subjects with severe renal insufficiency
(group IV). However, this small change in ceftibuten-cis
Cmax and Tm,. may not be clinically significant.
The Cmax, Tmax, AUCO, and t1/2, values of ceftibuten-
trans were significantly larger in the subjects with severe
renal impairment not undergoing hemodialysis. Although the
ratio of ceftibuten-trans to ceftibuten-cis AUCOO was not
significantly different between subjects in the four groups,
the P value was 0.078. Given these changes and the fact that
ceftibuten-cis f decreased as a function of CLCR, it can be
suggested that more drug may be metabolized to ceftibuten-
trans in these severely impaired subjects. There was not a
statistically significant difference Iin the CLR of ceftibuten-
trans; however, this may have been due to insufficient
statistical power. The t,/2,3 of ceftibuten-trans was not dif-ferent from the tl/2,3 of ceftibuten-cis, therefore suggesting
that the P of ceftibuten-trans is formation rate limited. The
percentage of the administered dose of ceftibuten recovered
in urine as ceftibuten-cis plus ceftibuten-trans was signifi-
cantly greater in group I and II subjects than it was in
subjects in groups III and IV (77.6 + 13.5, 67.8 ± 10.7, 55.7
+ 17.5, and 46.5 + 15.3%, respectively).
Several methods for modification of the antibiotic dosage
recommendation in subjects with reduced renal function
have been suggested (4, 13). To achieve the same average
concentration in plasma in subjects with impaired renal
function as that in normal subjects, the dose can be kept
constant and the dosing interval can be changed. Alterna-
tively, the dosing interval can be kept constant and the dose
can be altered. Both of these methods give similar average
steady-state concentrations, but they yield vastly different
effects on the maximum and minimum drug concentrations.
Ceftibuten, as with most other cephalosporins, has not
been associated with any concentration-dependent toxicity.
Consequently, ceftibuten dose adjustments may not be nec-
essary from a toxicity standpoint. However, dosage adjust-
ments could yield a significant cost savings by reducing
the amount of drug required to achieve and maintain thera-
peutic concentrations. The MIC for 90% of mo'st ceftibuten-
susceptible organisms ranges between 0.025 to 0.4 mg/liter.
However, clinical response has been demonstrated with
once-daily administration of ceftibuten, in which the concen-
trations in plasma may not exceed the MIC for the entire
dosing interval (3). In randomized, single-blind trials, cefti-
buten administered once daily at doses of 400 mg (or 6 mg/kg
in children) demonstrated a response rate of 92 and 94%
against streptococcal pharyngitis and otis media infections,
respectively (8). In patients with bronchitis treated with 400
mg of ceftibuten once daily, the infecting pathogens were
eliminated from 85% of cases and the clinical response rate
was 91% (8). Similar response data for the treatment of
urinary tract infections, pneumonia, and sinusitis infections
with ceftibuten given at 400 mg once daily also have been
defined (12). On the basis of a dose of 400 mg of ceftibuten
given orally every 24 h, the dose of ceftibuten should not
need alteration until the CLCR drops below 49 ml/min. Table
5 lists dosage adjustments and projected Cm,,, and trough
concentrations in plasma for ceftibuten on the basis of
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TABLE 5. Ceftibuten dosage regimen intervala
Subject CLCR Dose Cmax Trough ceftibuten
group (ml/min) (mg) (mg/liter) concn (mg/liter)
Group I >80 400 10.1 0.04
Group II 50-79 400 14.0 0.2
Group III 30-49 200 7.8 0.9
Group IV 5-29 100 7.1 1.7
Group V 300a 20.0 1.5
a Ceftibuten was given to subjects in groups I to IV once every 24 h;
hemodialysis patients received ceftibuten at 300 mg three times weekly, after
hemodialysis.
CLCR, assuming a 90% F (1) and utilizing the average
pharmacokinetic parameters for the CLCR group.
Ceftibuten is a low-molecular-weight compound that is
soluble in water and has a relatively low extent of protein
binding (although that was not assessed in the subjects in this
study); therefore, as anticipated, much of it was removed by
hemodialysis. The fraction of the ceftibuten dose removed
during the 3-h hemodialysis procedure was 39%, and the
CLHD of ceftibuten-cis was 25.6 and 34.8% of the simulta-
neous CLHD of BUN and creatinine, respectively. There-
fore, in order to maintain effective concentrations of cefti-
buten in plasma, a 300-mg dose of ceftibuten given three
times weekly after hemodialysis should achieve effective
concentrations in plasma (Cmax of 20 mg/liter and a trough
concentration after hemodialysis of 1.5 mg/liter). These
proposed dosage regimens need to be validated for their
efficacy in infected patients.
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